Peking University Cancer Hospital

Running trials

• Recruiting

  Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy

  NCT07789184· Phase 3· Hua Huang, MD, PhD· Source

• Not yet recruiting

  A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT07865910· Phase 2/3· Shanghai Henlius Biotech· Source

• Not yet recruiting

  A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC

  NCT07720193· Phase 3· Nanjing Leads Biolabs Co.,Ltd· Source

• Not yet recruiting

  RC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ Adenocarcinoma

  NCT07935369· Phase 2/3· RemeGen Co., Ltd.· Source

• Not yet recruiting

  Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer

  NCT07821606· Phase 3· Hansoh BioMedical R&D Company· Source

• Not yet recruiting

  Diagnostic Performance of an AI-Based Multi-Omics Model for Early Lung Cancer

  NCT07882628· Beijing Chao Yang Hospital· Source

• Not yet recruiting

  SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular Carcinoma

  NCT07882056· Phase 2· Peking University Cancer Hospital & Institute· Source

• Recruiting

  A Study of BL-M08D in Patients With Locally Advanced or Metastatic Melanoma and Other Solid Tumors

  NCT07841925· Phase 1/2· Sichuan Baili Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  NCT07808827· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

  NCT07541170· Phase 3· Hoffmann-La Roche· Source

• Not yet recruiting

  A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation

  NCT07814417· Phase 2· Eli Lilly and Company· Source

• Not yet recruiting

  Risk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and Surgery

  NCT07822906· Peking University Cancer Hospital & Institute· Source

• Recruiting

  EMB-01 in Combination With Chemotherapy for Unresectable or Metastatic Colorectal Cancer

  NCT07649655· Phase 1· Shanghai EpimAb Biotherapeutics Co., Ltd.· Source

• Recruiting

  Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

  NCT07700979· Phase 3· Akeso· Source

• Recruiting

  QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ

  NCT07716449· Phase 3· Qilu Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

  NCT07795346· Phase 3· Antengene Biologics Limited· Source

• Recruiting

  A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum

  NCT07811193· Phase 2· Vividion Therapeutics, Inc.· Source

• Recruiting

  Real World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung Cancer

  NCT07806604· Betta Pharmaceuticals Co., Ltd.· Source

• Recruiting

  Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)

  NCT07778316· Phase 3· Amgen· Source

• Recruiting

  A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal Cancer

  NCT07676162· Phase 3· Suzhou Suncadia Biopharmaceuticals Co., Ltd.· Source

• Recruiting

  Clinical Study of HS-IT101 Injection in the Treatment of Advanced Renal Cancer(FASTIL-Renal01)

  NCT07770802· Phase 1· Hangzhou Huasai Biomedicine Co., Ltd.· Source

• Recruiting

  A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer

  NCT07805551· Phase 1/2· Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.· Source

• Recruiting

  HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer

  NCT07790510· Phase 1/2· Haisco Pharmaceutical Group Co., Ltd.· Source

• Recruiting

  SMP-656 for HER2-Positive Advanced Breast Cancer

  NCT07726342· Phase 2· Chengdu SciMount Pharmatech Co., Ltd.· Source

• Not yet recruiting

  A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer

  NCT07737600· Phase 1/2· Lepu Biopharma Co., Ltd.· Source

• Recruiting

  Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC

  NCT07733830· Phase 2· Tianjin Medical University Cancer Institute and Hospital· Source

• Not yet recruiting

  SHR-A1904 in Advanced Colorectal Cancer: an Exploratory Study

  NCT07700719· Phase 2· Peking University Cancer Hospital & Institute· Source

• Recruiting

  A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC

  NCT07586202· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations

  NCT07640295· Phase 1/2· Jacobio Pharmaceuticals Co., Ltd.· Source

• Recruiting

  A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)

  NCT07622186· Phase 2· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source

• Not yet recruiting

  A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer

  NCT07621159· Phase 1/2· Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma

  NCT07586124· Phase 2· Lepu Biopharma Co., Ltd.· Source

• Not yet recruiting

  A Clinical Study GK01 Cell Injection in Subjects With Advanced Lung Cancer

  NCT07673419· Early phase 1· Beijing Geekgene Technology Co., LTD· Source

• Recruiting

  Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

  NCT07489066· Phase 2· Pfizer· Source

• Recruiting

  A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)

  NCT07582315· Phase 3· Sichuan Baili Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

  NCT07634471· Phase 2/3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

  NCT07554339· Phase 3· Merck Sharp & Dohme LLC· Source

• Not yet recruiting

  Non-Operative Management and Following Immunotherapy for Colorectal Cancer and Other GI Cancers

  NCT07656740· Peking University Cancer Hospital & Institute· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

  NCT07562022· Phase 3· Sinocelltech Ltd.· Source

• Recruiting

  A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)

  NCT07554456· Phase 2/3· Sichuan Baili Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  NCT07570823· Phase 3· Sinocelltech Ltd.· Source

• Not yet recruiting

  A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.

  NCT07623642· Phase 2· GV20 Therapeutics· Source

• Not yet recruiting

  5T4 Targeting Nanobody Probe for PET Imaging in Solid Tumors

  NCT07589101· Peking University Cancer Hospital & Institute· Source

• Recruiting

  Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma

  NCT05321316· Peking University Cancer Hospital & Institute· Source

• Active, not recruiting

  HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion

  NCT07466225· Peking University· Source

• Not yet recruiting

  A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors

  NCT07583316· Phase 1· Corregene Biotechnology Co., Ltd· Source

• Recruiting

  RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

  NCT07413939· Phase 2/3· Hoffmann-La Roche· Source

• Recruiting

  A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment

  NCT07518147· Phase 3· Biokin (Shanghai) Biopharmaceutical Co., Ltd.· Source

• Recruiting

  A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer

  NCT07462143· Phase 2/3· RemeGen Co., Ltd.· Source

Showing 50 of 429.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer86 recruiting
• Gastric and oesophageal cancer63 recruiting
• Colorectal cancer45 recruiting
• Pancreatic cancer24 recruiting
• Liver and biliary tract cancer22 recruiting
• Melanoma22 recruiting
• Prostate cancer13 recruiting
• Metastatic breast cancer12 recruiting
• Bladder cancer11 recruiting
• Ovarian cancer11 recruiting
• Childhood cancers10 recruiting
• Follicular lymphoma10 recruiting
• Endometrial cancer9 recruiting
• Head and neck cancer9 recruiting
• Kidney cancer9 recruiting
• Triple-negative breast cancer9 recruiting
• Sarcoma7 recruiting
• Diffuse large B-cell lymphoma6 recruiting
• Cervical cancer4 recruiting
• Mantle cell lymphoma4 recruiting
• Neuroendocrine tumours4 recruiting
• Brain metastases3 recruiting
• Thyroid cancer3 recruiting
• Glioblastoma2 recruiting
• Hodgkin lymphoma2 recruiting
• Acute myeloid leukaemia1 recruiting
• Mesothelioma1 recruiting
• Myelodysplastic syndromes1 recruiting

Closed trials

• Completed

  HS-IT101 Injection in the Treatment of Advanced Melanoma(FASTIL-Mela01)

  NCT06941818· Phase 1· Hangzhou Huasai Biomedicine Co., Ltd.· Source

• Terminated

  Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer

  NCT06897579· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Completed

  Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors

  NCT06806046· Phase 1· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Source

• Terminated

  A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

  NCT06585488· Phase 1· BeOne Medicines· Source

• Completed

  A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)

  NCT06624059· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China

  NCT06585501· Daiichi Sankyo· Source

• Completed

  A Study of Real-world Treatment Patterns and Outcomes in Chinese Advanced NSCLC Patients Who Previously Received at Least 2 Line Treatments

  NCT06617390· Daiichi Sankyo· Source

• Completed

  ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer

  NCT06498479· Phase 3· Hansoh BioMedical R&D Company· Source

• Recruiting

  A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

  NCT06385080· Phase 1/2· Janssen Research & Development, LLC· Source

• Completed

  BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

  NCT06253195· Phase 1· BeOne Medicines· Source

• Completed

  Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors

  NCT06091748· Phase 3· Jiangsu HengRui Medicine Co., Ltd.· Source

• Terminated

  TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors

  NCT06438783· Phase 1· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source

• Completed

  The Safety and Efficiency of Stent-based Diverting Technique Versus Ileostomy in Rectal Cancer Patients

  NCT06204497· Sir Run Run Shaw Hospital· Source

• Completed

  RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

  NCT06173037· Phase 2· RemeGen Co., Ltd.· Source

• Completed

  Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT06091943· Phase 1· BeiGene· Source

• Completed

  A Study of GC101 TIL in Advanced Melanoma (BZ)

  NCT06120712· Phase 1/2· Shanghai Juncell Therapeutics· Source

• Terminated

  KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer

  NCT05985109· Phase 2· Peking University Cancer Hospital & Institute· Source

• Completed

  A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

  NCT05909904· Phase 2· BeiGene· Source

• Completed

  A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China

  NCT05896774· Phase 1· Pfizer· Source

• Terminated

  Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRC

  NCT05584137· Phase 2· Shanghai Henlius Biotech· Source

• Withdrawn

  A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC

  NCT05212922· Phase 2· Eucure (Beijing) Biopharma Co., Ltd· Source

• Completed

  A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

  NCT05805501· Phase 2· Hoffmann-La Roche· Source

• Completed

  Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

  NCT05577702· Phase 2· BeiGene· Source

• Terminated

  A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma

  NCT05720052· Phase 1/2· MingSight Pharmaceuticals, Inc· Source

• Completed

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903

  NCT06846099· Phase 1· Risen (Suzhou) Pharma Tech Co., Ltd.· Source

• Completed

  Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer

  NCT05555706· Phase 2/3· Shanghai Jiaolian Drug Research and Development Co., Ltd· Source

• Completed

  Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma

  NCT05263583· Phase 2· Cothera Bioscience, Inc· Source

• Terminated

  Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

  NCT05461794· Phase 2· BeiGene· Source

• Terminated

  A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors

  NCT05501912· Phase 1· ABM Therapeutics Shanghai Company Limited· Source

• Completed

  Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

  NCT05383482· Phase 1/2· Laekna Limited· Source

• Completed

  Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

  NCT05267054· Phase 1/2· BeiGene· Source

• Completed

  To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

  NCT05253053· Phase 1/2· TransThera Sciences (Nanjing), Inc.· Source

• Completed

  Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT05218499· Phase 2/3· Boehringer Ingelheim· Source

• Terminated

  A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

  NCT05242822· Phase 1· Kinnate Biopharma· Source

• Completed

  Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05052801· Phase 3· Amgen· Source

• Terminated

  Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer

  NCT05149807· Phase 2/3· Suzhou Suncadia Biopharmaceuticals Co., Ltd.· Source

• Completed

  A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)

  NCT05144841· Phase 2· Merck Sharp & Dohme LLC· Source

• Terminated

  Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.

  NCT05171166· Phase 2/3· Peking University· Source

• Completed

  A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma

  NCT05051891· Phase 3· Beijing InnoCare Pharma Tech Co., Ltd.· Source

• Completed

  Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC

  NCT05969184· Phase 2· Peking University Cancer Hospital & Institute· Source

• Completed

  Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

  NCT05014815· Phase 2· BeiGene· Source

• Completed

  A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma

  NCT05008783· Phase 3· Akeso· Source

• Completed

  A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.

  NCT05004350· Phase 2· Pierre Fabre Medicament· Source

• Completed

  Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT4706 in Advanced Solid Tumors

  NCT05148325· Phase 1· Bio-Thera Solutions· Source

• Completed

  A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC

  NCT04948697· Phase 2· BeiGene· Source

• Terminated

  A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

  NCT04933227· Phase 2· Hoffmann-La Roche· Source

• Terminated

  Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).

  NCT04949256· Phase 3· Merck Sharp & Dohme LLC· Source

• Terminated

  Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT04921358· Phase 3· BeiGene· Source

• Terminated

  AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer

  NCT04993391· Phase 1/2· Suzhou Junjing BioSciences Co., Ltd.· Source

• Recruiting

  Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

  NCT04886804· Phase 1· Boehringer Ingelheim· Source

Showing 50 of 138.

Conditions

Diseases this institution publishes on or runs trials for.

• Lung cancer273 works · 189 trials
• Gastric and oesophageal cancer172 works · 102 trials
• Colorectal cancer117 works · 65 trials
• Liver and biliary tract cancer78 works · 48 trials
• Melanoma56 works · 37 trials
• Bladder cancer40 works · 19 trials
• Ovarian cancer37 works · 24 trials
• Triple-negative breast cancer31 works · 16 trials
• Cervical cancer27 works · 7 trials
• Sarcoma26 works · 13 trials
• Brain metastases20 works · 4 trials
• Metastatic breast cancer20 works · 29 trials
• Neuroendocrine tumours13 works · 9 trials
• Mantle cell lymphoma10 works · 15 trials
• Diffuse large B-cell lymphoma10 works · 20 trials
• Thyroid cancer9 works · 8 trials
• Follicular lymphoma5 works · 17 trials
• Mesothelioma5 works · 1 trial